On August 7, Moderna, Inc. rose 5.31% in regular trading, trading at $56.705/share, with turnover of $69.93 million. The rally was driven by the company's announcement that its seasonal influenza vaccine mFLUSIVA officially received U.S. FDA approval.

The approval covers use in adults aged 50 and above, marking the first mRNA-based vaccine to enter the flu market and Moderna's fourth FDA-cleared product in the U.S. The company expects the vaccine to become available for the 2026-2027 respiratory virus season, with retail availability anticipated within weeks. The vaccine is also under regulatory review in Australia, Canada, and Europe, suggesting further upside from global commercialization.

The approval came after a period of rare public disagreement between Moderna and FDA regulators, making the clearance a significant milestone. Multiple institutions had recently raised price targets ahead of the PDUFA date, including UBS to $50 and Goldman Sachs to $67, while the company's Q2 EPS of -$1.97 also beat consensus estimates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)